Table 3.
Treatment group | Mg (mg dL−1) | Ca (mg dL−1) | P inorganic (mg dL−1) | ALP (UI L−1) |
---|---|---|---|---|
30-day treatment | ||||
SHAM | 2.43 ± 0.06 | 10.6 ± 0.01 | 6.29 ± 0.43 | 103 ± 13.65 |
C-OVX | 2.41 ± 0.07 | 10.18 ± 0.18 | 7.18 ± 0.3 | 81.6 ± 3.98 |
F-OVX | 2.43 ± 0.04 | 10.56 ± 0.1 | 6.09 ± 0.22 | 144.6 ± 15.4**,#,++ |
EB-OVX | 2.48 ± 0.05 | 10.52 ± 0.1 | 6.57 ± 0.25 | 75 ± 12.5 |
60-day treatment | ||||
SHAM | 2.57 ± 0.06 | 10.25 ± 0.16 | 7.52 ± 0.46 | 89.5 ± 9.24 |
C-OVX | 2.86 ± 0.4 | 10.28 ± 0.02 | 6.2 ± 0.22# | 90.2 ± 8.61 |
F-OVX | 2.55 ± 0.07 | 10.58 ± 0.12 | 6.37 ± 0.27# | 109.2 ± 7.19+ |
EB-OVX | 2.47 ± 0.04 | 10.58 ± 0.14 | 6.02 ± 0.17# | 72.8 ± 5.91 |
All values are expressed as mean ± SEM.
anova followed by Newman–Keuls test:
P< 0.01 vs. C-OVX;
P< 0.05,
P< 0.01 vs. EB-OVX;
P< 0.05 vs. SHAM.
SHAM, sham-operated controls receiving vehicle; C-OVX, ovariectomized controls receiving vehicle; F-OVX, ovariectomized treated with ferutinin; EB-OVX, ovariectomized treated with estradiol benzoate.